CASI Pharmaceuticals, Inc. Ordinary Shares

CASIStock

$0.00−27.08%52W

Market Cap$2.49M

P/E—

Div yield—

Beta0.43

Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-95.90%

Price vs S&P 500 (4W)-80.09%

VGM Score54.36

Market Capitalization$2.49M

Earnings Surprise History

Q4 25-0.80est. -0.37

Analyst Recommendations

Mar 2023

Apr 2023

May 2023

Jun 2023

4.25

4.14

About

CASI Pharmaceuticals is a specialized biopharmaceutical company focused on oncology therapies for hematologic malignancies including leukemia, lymphoma, and multiple myeloma. The company's marketed products include EVOMELA, a conditioning agent for autologous stem cell transplant in multiple myeloma patients, along with MARQIBO and ZEVALIN. EVOMELA is the primary revenue driver.